Introduction
Incretin-based pharmacotherapy has undergone a rapid evolution over the past two decades, progressing from single-target glucagon-like peptide-1 (GLP-1) receptor agonists to multi-receptor agonists with broader metabolic activity. The incretin system, which modulates postprandial insulin secretion and energy homeostasis, has proven to be a highly tractable axis for therapeutic intervention in type 2 diabetes mellitus (T2DM) and obesity (Nauck et al., 2021). Single-receptor GLP-1 agonists such as semaglutide and liraglutide demonstrated significant glycaemic and weight-reducing effects, establishing the clinical validity of this approach (Müller et al., 2019). The subsequent development of tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, demonstrated that multi-receptor engagement could further amplify metabolic outcomes.
Retatrutide (LY3437943) represents the next iteration in this progression: a single peptide engineered to simultaneously activate three distinct receptors — the GIP receptor (GIPR), the GLP-1 receptor (GLP-1R), and the glucagon receptor (GCGR). This triple-agonist approach was hypothesised to harness the complementary metabolic actions of all three hormones, potentially achieving greater reductions in body weight and improvements in glycaemic control than dual or single agonists (Coskun et al., 2022). The preclinical rationale for this strategy drew upon foundational work demonstrating that glucagon and GLP-1 co-agonism produced synergistic effects on energy expenditure and adiposity in rodent models (Day et al., 2009).
Mechanism of Action
Triple Receptor Agonism
Retatrutide is a 39-amino acid peptide based on a modified GIP sequence, engineered with substitutions that confer activity at all three target receptors. The molecule incorporates a C20 fatty diacid moiety conjugated via a linker, facilitating albumin binding and thereby extending its circulating half-life to support once-weekly subcutaneous administration (Coskun et al., 2022). In vitro receptor binding assays have demonstrated that retatrutide activates GIPR, GLP-1R, and GCGR with a potency ratio of approximately 1:1:1 relative to native ligands, although the precise activity profile is dose-dependent and subject to receptor desensitisation dynamics.
GLP-1 Receptor Component
The GLP-1R agonist activity of retatrutide contributes to glucose-dependent insulin secretion, suppression of inappropriately elevated glucagon in the postprandial state, delayed gastric emptying, and central appetite suppression via hypothalamic and brainstem signalling pathways (Müller et al., 2019). These are well-characterised actions shared with existing GLP-1 receptor agonists and represent the established mechanistic foundation upon which the multi-agonist strategy is built.
GIP Receptor Component
The contribution of GIPR agonism to metabolic outcomes is an area of active investigation. GIP signalling enhances beta-cell insulin secretion in a glucose-dependent manner and may potentiate the insulinotropic effects of GLP-1R activation through complementary intracellular signalling cascades (Samms, Coghlan and Sloop, 2020). Additionally, GIPR agonism has been implicated in the regulation of lipid metabolism within adipose tissue, potentially promoting more efficient lipid handling and storage. The synergistic interaction between GIP and GLP-1 receptor co-activation is considered a key differentiator of dual and triple agonists compared to GLP-1 monotherapy.
Glucagon Receptor Component
The inclusion of GCGR agonism distinguishes retatrutide from dual GIP/GLP-1 agonists and introduces additional metabolic effects. Glucagon promotes hepatic glycogenolysis and gluconeogenesis, but also stimulates energy expenditure through thermogenesis, enhances hepatic lipid oxidation, and reduces hepatic lipid content (Habegger et al., 2010). Preclinical studies in rodent models demonstrated that the addition of glucagon receptor agonism to GLP-1 activity resulted in increased energy expenditure that was not observed with GLP-1 agonism alone (Day et al., 2009). Importantly, the concurrent GLP-1R activation is proposed to counterbalance glucagon-induced hyperglycaemia, maintaining glycaemic neutrality or even net glucose-lowering effects. The triagonist concept was first validated preclinically by Finan et al. (2015), who demonstrated that a rationally designed monomeric triagonist peptide corrected obesity and diabetes in rodent models with superior efficacy relative to dual agonists (Finan et al., 2015).
Key Clinical Research Findings
Phase 2 Trials in Obesity
The pivotal phase 2 trial published in the New England Journal of Medicine enrolled 338 adults with obesity (body mass index ≥30 kg/m², or ≥27 kg/m² with at least one weight-related comorbidity) in a 48-week, randomised, double-blind, placebo-controlled, dose-finding study (Jastreboff et al., 2023). Participants were randomly assigned to one of several retatrutide dose groups (ranging from 1 mg to 12 mg administered subcutaneously once weekly) or placebo.
At the 12 mg dose level, participants achieved a mean body weight reduction of approximately 24.2% from baseline at 48 weeks, a magnitude of weight loss that exceeded prior results reported for both semaglutide and tirzepatide at comparable timepoints. Notably, the weight trajectory at 48 weeks had not yet reached a plateau, suggesting that longer treatment durations may yield further reductions. These results represented, at the time of publication, the largest mean percentage weight reduction reported in a clinical trial of any anti-obesity pharmacotherapy (Jastreboff et al., 2023).
Phase 2 Trials in Type 2 Diabetes
A concurrent phase 2 trial assessed the glycaemic efficacy and safety of retatrutide in 281 adults with T2DM, using dulaglutide 1.5 mg as an active comparator (Rosenstock et al., 2023). Over 36 weeks, retatrutide at the 12 mg dose produced a mean reduction in glycated haemoglobin (HbA1c) of approximately 2.02 percentage points from a baseline of 8.3%, compared to 1.41 percentage points with dulaglutide. At 36 weeks, 71% of participants in the 12 mg retatrutide group achieved an HbA1c below 5.7%, a threshold considered within the normoglycaemic range.
Body weight reductions in the T2DM cohort were also substantial, with the 12 mg group achieving a mean loss of 16.9% at 36 weeks. The safety profile was generally consistent with that observed in the obesity trial, with gastrointestinal adverse events (nausea, diarrhoea, vomiting) being the most frequently reported treatment-emergent events, and these were predominantly mild to moderate in severity and tended to diminish with continued dosing (Rosenstock et al., 2023).
Pharmacokinetics
Retatrutide exhibits pharmacokinetic properties engineered for once-weekly subcutaneous dosing. The C20 fatty diacid side chain promotes non-covalent binding to serum albumin, reducing renal clearance and extending the elimination half-life to approximately five to six days (Coskun et al., 2022). Steady-state plasma concentrations are generally achieved after three to four weekly administrations. The dose escalation protocols employed in the phase 2 clinical programmes — initiating at lower doses and incrementally increasing over several weeks — were implemented to attenuate gastrointestinal tolerability issues during the period of rising drug exposure.
Gastric emptying studies confirmed that retatrutide produces a significant delay in gastric emptying, a pharmacodynamic effect attributable primarily to its GLP-1R agonist activity and one that contributes to postprandial glucose control and reduced caloric intake (Urva et al., 2023). This effect was observed across the dose range evaluated and represents a shared mechanism with other incretin-based therapies.
Current Research Directions
Retatrutide has advanced to phase 3 clinical development across multiple indications. The TRIUMPH programme encompasses several large-scale, registrational trials designed to confirm the efficacy and safety findings from phase 2 in broader patient populations. These trials are evaluating retatrutide in adults with obesity, with and without T2DM, and are anticipated to provide the data necessary to support regulatory submissions.
Beyond its primary metabolic indications, the pharmacological profile of retatrutide — particularly its glucagon receptor agonism and associated hepatic lipid oxidation — has generated considerable interest in its potential application to metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD). The capacity to simultaneously reduce body weight, improve insulin sensitivity, and directly promote hepatic lipid clearance represents a mechanistic rationale for efficacy in this setting that is being explored in dedicated trials.
Additional areas of investigation include the cardiovascular safety and potential cardiovascular benefit of retatrutide, the durability of weight loss upon treatment cessation, and the comparative efficacy of triple versus dual agonism in head-to-head studies. The question of whether the addition of glucagon receptor agonism translates to clinically meaningful advantages in energy expenditure and hepatic outcomes remains an important subject of ongoing research (Coskun et al., 2022).
Collectively, the clinical data generated to date position retatrutide as a notable molecule in the evolving landscape of multi-receptor agonist pharmacotherapy. The unprecedented weight reductions observed in phase 2, if confirmed in phase 3, would represent a substantial advance in the pharmacological management of obesity and may redefine expectations for what is achievable through incretin-based intervention.